Andrew Leber, PhD

NIMML Institute
Blacksburg

Dr. Leber has a background in immunology, engineering and computational biology. His research focuses on the identification of novel anti-inflammatory targets in Tregs and other immune cells. He has led the discovery and development of multiple drugs currently in clinical development in the autoimmune disease space with focus on IBD and lupus.

Presentation(s):

• 2337: Safety and Tolerability of NIM-1324, an Oral, Once-daily LANCL2 Agonist, in a Randomized, Double-Blind, Placebo-Controlled Phase 1 Study in Normal Healthy Volunteers

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.